BioCentury | Mar 18, 2002
Finance

Ebb & Flow

...Venture Partners, Kleiner Perkins Caufield & Byers, MDS Capital, Boston Millennia Partners, Levensohn Capital Management, Moss Forest Ventures...
BioCentury | Oct 22, 2001
Finance

Ebb & Flow

Trading in Genzyme (GENZ) provided for some read as to how the market weighs current EPS vs. potential future profits. GENZ's solid third quarter results and a boost in revenue projections for its Renagel phosphate...
BioCentury | Oct 17, 2001
Financial News

GeneFormatics raises $22 million

GeneFormatics (San Diego, Calif.), which is using in silico technologies to analyze human protein sequences and pathogen proteomes, raised $22 million in a private financing. Investors included Bruker AXS; Bruker BioSpin; Bruker Daltonics (BDAL); TaKaRa...
BioCentury | Oct 5, 2000
Financial News

GeneFormatics raises $15 million

Proteomics play GeneFormatics (San Diego, Calif.) raised $15 million in a private round. Investors included Perseus-Soros BioPharmaceutical Fund; Merrill Lynch Ventures; OrbiMed Advisors; GeneChem Management; Burrill & Co.; Inglewood Ventures; and Moss Forest Venture. BC...
BioCentury | Aug 7, 2000
Company News

Silico Insights Inc. board of directors update

...of Ashni Nutraceuticals Inc. and Salus Therapeutics Inc. ; and Frank Montgomery, general partner at Moss Forest Ventures WIR...
BioCentury | Feb 23, 2000
Company News

On-line genomic collaboration

...Mayfield Fund; Kleiner Perkins Caufield and Byers; MDS Capital; Boston Millennia Partners; Burrill and Co.; Moss Forest Ventures...
Items per page:
1 - 6 of 6
BioCentury | Mar 18, 2002
Finance

Ebb & Flow

...Venture Partners, Kleiner Perkins Caufield & Byers, MDS Capital, Boston Millennia Partners, Levensohn Capital Management, Moss Forest Ventures...
BioCentury | Oct 22, 2001
Finance

Ebb & Flow

Trading in Genzyme (GENZ) provided for some read as to how the market weighs current EPS vs. potential future profits. GENZ's solid third quarter results and a boost in revenue projections for its Renagel phosphate...
BioCentury | Oct 17, 2001
Financial News

GeneFormatics raises $22 million

GeneFormatics (San Diego, Calif.), which is using in silico technologies to analyze human protein sequences and pathogen proteomes, raised $22 million in a private financing. Investors included Bruker AXS; Bruker BioSpin; Bruker Daltonics (BDAL); TaKaRa...
BioCentury | Oct 5, 2000
Financial News

GeneFormatics raises $15 million

Proteomics play GeneFormatics (San Diego, Calif.) raised $15 million in a private round. Investors included Perseus-Soros BioPharmaceutical Fund; Merrill Lynch Ventures; OrbiMed Advisors; GeneChem Management; Burrill & Co.; Inglewood Ventures; and Moss Forest Venture. BC...
BioCentury | Aug 7, 2000
Company News

Silico Insights Inc. board of directors update

...of Ashni Nutraceuticals Inc. and Salus Therapeutics Inc. ; and Frank Montgomery, general partner at Moss Forest Ventures WIR...
BioCentury | Feb 23, 2000
Company News

On-line genomic collaboration

...Mayfield Fund; Kleiner Perkins Caufield and Byers; MDS Capital; Boston Millennia Partners; Burrill and Co.; Moss Forest Ventures...
Items per page:
1 - 6 of 6